MBX vs BGSI
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
MBX · MBX Biosciences$51.35 ▲ 5.96%
BGSI · Boyd Group Services$88.72 ▼ 1.62%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- MBX +109.7%
- BGSI -41.2%
Head to head
| Metric | MBX | BGSI |
|---|---|---|
| Price | $51.35 | $88.72 |
| Change today | ▲ 5.96% | ▼ 1.62% |
| Market cap | $2.47B | $2.47B |
| Return, 3 months | -22.4% | -12.1% |
| Return, year to date | +62.8% | -44.1% |
| Return, 1 year | +100.8% | -40.9% |
| P/E (TTM) | – | 197.2 |
| P/B | 6.0 | 1.4 |
| P/E percentile vs own 5y | 13th | 68th |
| Dividend yield | – | 0.50% |
| Revenue growth (YoY, latest qtr) | – | +29.9% |
| Net profit growth (YoY) | -91.1% | -76.2% |
| Gross margin | – | 46.7% |
| Operating margin | – | 4.5% |
| Net margin | – | 0.3% |
| Return on equity | -33.2% | 0.7% |
| Analyst target vs. price | +100.9% | +59.5% |
| Analyst buy share | 100% | 89% |
| RSI (14) | 45 | 62 |
| 30-day volatility | 62.0% | 32.6% |
| Max drawdown, 1 year | -37.6% | -57.7% |
| Trend read | Leaning bearish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MBX is the largest of the group by market value.
- MBX has returned the most over the past year.
- BGSI has been the calmest stock over the last 30 days.